Oral sodium bicarbonate therapy given to patients with chronic kidney disease increases urinary pH but also increases urinary citrate levels, which may mitigate the risk for calcium phosphate stone formation.
An analysis of contemporary ESA utilization among patients with anemia of nondialysis-dependent chronic kidney disease may help identify optimal candidates for treatment.
The downstream effects of medical care reduction on health outcomes, such as hospitalizations or dialysis preparedness, requires further study, according to the investigators.
